brodalumab

Modality

mAb

Mechanism

12.1 Mechanism of Action Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL-17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.

Targets

IL-17 receptor complex, IL-17A

Storage

—

Approved

psoriasis — FDA

In trial

psoriasis, acne vulgaris, hidradenitis suppurativa

Sources

DailyMed (FDA label)DrugBank ClinicalTrials.gov

Last verified

2026-06-14

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by brodalumab.

Monitoring & workup

Baseline workup

•TB IGRA (or PPD)
•HBV sAg if high risk; HCV Ab if high risk
•Update age-appropriate vaccines before start

Ongoing monitoring

•No routine labs
•Annual TB screening if high exposure risk
•IL-17 class: monitor for candida overgrowth + IBD flare
•IL-23 class: monitor for injection-site reactions